Note: Videos will get better with time...
GILD Fundamental Review via Illustrations:
Mkt Cap - $83B, Enterprise Value - $107
P/S ratio under 3
High P/E ratio currently based on accounting loss; Acquired in-process R&D
Cash & Debt balances hit recently due to acquisitions of:
Forty Seven - $4.7B
Immunomedics - $20.4B
Such impacts adjusted Mkt Cap and Enterprise Values relative values greatly
As with many pharmaceutical with approved drug candidates, solid dividend
Dividend over 4%
Last dividend $0.71/share; growth over time per chart
AIDS: Biktarvy, Genvoya, Descovy, Odefsey
Liver: Hep-C – Sofosbuvir/Velpatasvir
COVID-19 – Veklury (remdesivir) – what an addition – GILD stock not getting the love even though this may be temporary revenue stream. That said, I bet the revenues last longer than people expect
Options: How to hit on this more via person experience
Revenue Growth one of the most important images
Growth increasing recently
HCV declines behind them and AIDS/COVID-19 powering growth
As noted before, recent acquisitions have hit the cash pile. This is a risk, I don’t like debt levels at these levels, so will watch with time.
R&D up due to acquired in process R&D
Based on GAAP numbers P/E all over the place due to accounting rules
P/S ration consistently under 5
Get not a massive growth stock but relative to some of these companies trading at P/S ratios over 100, seems cheap.
Drugs Sale vs Time highlights the massive impact of Remdesivir on financials.
OVERALL: I don’t like the high debt loads, but the valuation and cash flow ability lead me to rate this stock as a BUY.